MX2021009761A - Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este. - Google Patents

Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este.

Info

Publication number
MX2021009761A
MX2021009761A MX2021009761A MX2021009761A MX2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A
Authority
MX
Mexico
Prior art keywords
diazabicyclo
octanylmethanone
pyrimidinyl
crystalline
compound
Prior art date
Application number
MX2021009761A
Other languages
English (en)
Spanish (es)
Inventor
Xiaojing Yang
Amanda Patrice Surajhie Samuel
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021009761A publication Critical patent/MX2021009761A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
MX2021009761A 2019-02-15 2020-02-12 Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este. MX2021009761A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806180P 2019-02-15 2019-02-15
PCT/IB2020/051128 WO2020165788A1 (en) 2019-02-15 2020-02-12 Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof

Publications (1)

Publication Number Publication Date
MX2021009761A true MX2021009761A (es) 2021-12-15

Family

ID=69726639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009761A MX2021009761A (es) 2019-02-15 2020-02-12 Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este.

Country Status (13)

Country Link
US (2) US12312358B2 (enExample)
EP (1) EP3924355B1 (enExample)
JP (1) JP7561497B2 (enExample)
KR (2) KR102820235B1 (enExample)
CN (1) CN113646310A (enExample)
AR (1) AR118099A1 (enExample)
AU (1) AU2020222083B2 (enExample)
BR (1) BR112021015951A2 (enExample)
CA (1) CA3130034C (enExample)
MX (1) MX2021009761A (enExample)
SG (1) SG11202108863WA (enExample)
TW (1) TWI820301B (enExample)
WO (1) WO2020165788A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI820301B (zh) * 2019-02-15 2023-11-01 美商輝瑞股份有限公司 結晶型嘧啶基-3,8-二氮雜雙環〔3.2.1〕辛烷基甲酮化合物及其用途
WO2021249367A1 (zh) * 2020-06-09 2021-12-16 苏州晶云药物科技股份有限公司 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
CN114835717A (zh) * 2021-02-01 2022-08-02 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5023556A (en) 1990-02-02 1991-06-11 Conax Florida Corporation Sensor circuit response to different fluid conductivities and having time delay feature
SI3290421T1 (sl) 2013-02-22 2019-03-29 Pfizer Inc. Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK)
NO2721710T3 (enExample) * 2014-08-21 2018-03-31
HUE067471T2 (hu) * 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
TWI820301B (zh) * 2019-02-15 2023-11-01 美商輝瑞股份有限公司 結晶型嘧啶基-3,8-二氮雜雙環〔3.2.1〕辛烷基甲酮化合物及其用途

Also Published As

Publication number Publication date
JP7561497B2 (ja) 2024-10-04
CN113646310A (zh) 2021-11-12
TWI820301B (zh) 2023-11-01
TW202045511A (zh) 2020-12-16
US20220144846A1 (en) 2022-05-12
AU2020222083A1 (en) 2021-09-02
US12312358B2 (en) 2025-05-27
CA3130034A1 (en) 2020-08-20
WO2020165788A1 (en) 2020-08-20
EP3924355A1 (en) 2021-12-22
SG11202108863WA (en) 2021-09-29
AU2020222083B2 (en) 2022-11-17
CA3130034C (en) 2023-12-19
KR20240116855A (ko) 2024-07-30
KR20210114470A (ko) 2021-09-23
KR102820235B1 (ko) 2025-06-16
JP2020138960A (ja) 2020-09-03
US20250282789A1 (en) 2025-09-11
AR118099A1 (es) 2021-09-15
EP3924355B1 (en) 2025-12-31
BR112021015951A2 (pt) 2021-10-05

Similar Documents

Publication Publication Date Title
MX2021009761A (es) Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este.
ZA202007671B (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
CR20200621A (es) Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
ECSP109979A (es) Preparación sólida que contiene alogliptina y clorhidrato de metformina
PE20191108A1 (es) Inhibidores selectivos de jak1
ECSP17046065A (es) Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional)
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
SG193245A1 (en) Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
MX2019011904A (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos.
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MX391567B (es) Agentes de imagenología nuevos para tomografía de emisión de positrones (pet) sustituidos con deuterio y su aplicación farmacológica.
BRPI0804091B8 (pt) compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm
MX2020007271A (es) Sales y cristales novedosos.
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
BR112022010377A2 (pt) Novos tiromiméticos
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
MX2022004686A (es) Composiciones farmaceuticas que comprenden (s)-2-(2,6-dioxopiperid in-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1- il)metil)bencil)indolin-1,3-diona y metodos de uso de las mismas.
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
WO2017139331A8 (en) Pharmaceutical bead formulations comprising dimethyl fumarate
BRPI0409217A (pt) derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona